Table 4

Patient characteristics and disease activity measures at baseline and 1 year of 327 polyarticular JIA patients and a weighted RA cohort starting first TNFi

Median (IQR) or %Polyarticular JIARA (weighted analysis)p Value (JIA compared with RA)
Gender, female85%85%1.000
Age at treatment start, years32 (24–42)32 (24–42)0.928
Age at disease onset, years13 (8–15)25 (20–34)0.001
Disease duration, years22 (14–32)5 (2–10)0.001
Ethnicity; white95%93%0.215
On methotrexate57%67%0.005
On steroids42%42%0.956
RF positive46%60%0.001
TNFi at registration (%)0.002
Total comorbidities* (%)0.377
Smoking status (%)0.397
 Current smoker2222
 Previous smoker1923
 Never smoked5955
 Baseline6.3 (5.6–7.0)6.3 (5.6–6.9)0.992
 1 year3.9 (2.8–5.0)3.8 (2.5–5.1)0.991
Change in DAS28 at 1 year−2.4 (−3.4 to −1.3)−2.6 (−3.6 to −1.2)0.589
EULAR response (%) at 1 year0.359
 No response1920
DAS28 remission (%) at 1 year23260.539
 Baseline2.0 (1.6–2.4)1.9 (1.4–2.3)0.005
 1 year1.6 (1.0–2.1)1.4 (0.8–2.0)0.033
Change in HAQ at 1 year−0.4 (−0.8 to −0.1)−0.5 (−0.8 to −0.1)0.523
HAQ MCID (%) at 1 year64660.775
  • *Comorbidities include; hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer, liver disease, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression, cancer.

  • DAS28, 28-joint Disease Activity Score; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JIA, Juvenile Idiopathic Arthritis; MCID, Minimally Clinical Important Difference; RA, Rheumatoid Arthritis; RF, Rheumatoid factor; TNFi, tumour necrosis factor inhibitor.